Our latest
News
Raising Pancreatic Cancer Awareness Through Patient Voices
Mauna Kea Technologies Celebrates Over 700 Procedures Performed in 18 Months at IECED-OMNI Hospital in Ecuador
Mauna Kea Technologies Announces Review of Strategic Alternatives
Mauna Kea Technologies Provides an Update on Its Recent Developments
Mauna Kea Technologies Announces New Positive Clinical Results for Cellvizio in Food Intolerance
Mauna Kea Technologies Reports H1 2024 Financial Results and Q3 2024 Sales
Mauna Kea Technologies Announces Ground-Breaking Positive Clinical Results in Lung Cancer Obtained with Cellvizio
Mauna Kea Technologies Announces Endorsement from The American Foregut Society for Payor Policy Coverage of Cellvizio®
Mauna Kea Technologies Announces its Sales and Achievements For the Second Quarter 2024
Mauna Kea Technologies Unveils CellTolerance, a Subsidiary Dedicated to its Unique Program for the Detection and Treatment of Food Intolerances
Mauna Kea Technologies Reports New Evidence Highly Supportive of the Use of Cellvizio for Diagnosing Pancreatic Cysts Presented at DDW 2024